Next Article in Journal
Musclin, A Myokine Induced by Aerobic Exercise, Retards Muscle Atrophy During Cancer Cachexia in Mice
Previous Article in Journal
PARP1 Co-Regulates EP300–BRG1-Dependent Transcription of Genes Involved in Breast Cancer Cell Proliferation and DNA Repair
Previous Article in Special Issue
A Novel Multi-Target Small Molecule, LCC-09, Inhibits Stemness and Therapy-Resistant Phenotypes of Glioblastoma Cells by Increasing miR-34a and Deregulating the DRD4/Akt/mTOR Signaling Axis
Open AccessArticle

Tumor Expression of Cyclin-Dependent Kinase 5 (Cdk5) Is a Prognostic Biomarker and Predicts Outcome of Oxaliplatin-Treated Metastatic Colorectal Cancer Patients

1
Program of predictive and personalized cancer medicine (PMPPC) Germans Trias i Pujol Research Institute (IGTP), Ctra. Can Ruti—Camí de les escoles s/n, 08916 Badalona, Spain
2
Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology, Ctra. Can Ruti- Camí de les escoles s/n, 08916 Badalona, Spain
3
Department of Pathology, Hospital Universitari Germans Trias i Pujol, Ctra. Can Ruti—Camí de les escoles s/n, 08916 Badalona, Spain
4
Department of Pathology, Hospital Universitari General de Catalunya, Grupo Quirónsalud, Pedro i Pons 1, 08195 Sant Cugat del Valles, Spain
5
Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology, 08908 L’Hospitalet del Llobregat, Barcelona, Spain
6
ONCOBELL Program, Bellvitge Institute for Biomedical Research, 08908 L’Hospitalet del Llobregat, Barcelona, Spain
7
Oncology Data Analytics Program, Institut Català d’Oncologia (ICO), 08908 Barcelona, Spain
8
Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), 28029 Madrid, Spain
9
Department of Clinical Sciences, Faculty of Medicine and Health Sciences, University of Barcelona, 08907 Barcelona, Spain
10
Group of Biomedical Research in Digestive Tract Tumors, CIBBIM-Nanomedicine, Vall d’Hebron University Hospital, Research Institute (VHIR), Universitat Autònoma de Barcelona, Passeig Vall d’Hebron, 119-129, 08035 Barcelona, Spain
11
Medical Oncology Service, Catalan Institute of Oncology (ICO), 08908, Spain
12
B-ARGO group, Germans Trias I Pujol Research Institute (IGTP), Ctra. Can Ruti- Camí de les escoles s/n, 08916 Badalona, Spain
*
Author to whom correspondence should be addressed.
Vicenç Ruiz de Porras and Sara Bystrup contributed equally.
Cancers 2019, 11(10), 1540; https://doi.org/10.3390/cancers11101540
Received: 5 September 2019 / Revised: 9 October 2019 / Accepted: 9 October 2019 / Published: 11 October 2019
In recent years, an increasing number of studies have shown that elevated expression of cyclin dependent kinase (Cdk5) contributes to the oncogenic initiation and progression of many types of cancers. In this study, we investigated the expression pattern of Cdk5 in colorectal cancer (CRC) cell lines and in a large number of tumor samples in order to evaluate its relevance in this pathogenesis and possible use as a prognostic marker. We found that Cdk5 is highly expressed and activated in CRC cell lines and that silencing of the kinase decreases their migration ability. In tumor tissues, Cdk5 is overexpressed compared to normal tissues due to a copy number gain. In patients with localized disease, we found that high Cdk5 levels correlate with poor prognosis, while in the metastatic setting, this was only the case for patients receiving an oxaliplatin-based treatment. When exploring the Cdk5 levels in the consensus molecular subtypes (CMS), we found the lowest levels in subtype 1, where high Cdk5 again was associated with a poorer prognosis. In conclusion, we confirm that Cdk5 is involved in CRC and disease progression and that it could serve as a prognostic and predictive biomarker in this disease.
Keywords: colorectal cancer; cyclin-dependent kinase 5 (Cdk5); prognostic and predictive biomarker; oxaliplatin colorectal cancer; cyclin-dependent kinase 5 (Cdk5); prognostic and predictive biomarker; oxaliplatin
MDPI and ACS Style

Ruiz de Porras, V.; Bystrup, S.; Cabrero-de las Heras, S.; Musulén, E.; Palomero, L.; Alonso, M.H.; Nieto, R.; Arango, D.; Moreno, V.; Queralt, C.; Manzano, J.L.; Layos, L.; Bugés, C.; Martinez-Balibrea, E. Tumor Expression of Cyclin-Dependent Kinase 5 (Cdk5) Is a Prognostic Biomarker and Predicts Outcome of Oxaliplatin-Treated Metastatic Colorectal Cancer Patients. Cancers 2019, 11, 1540.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop